vol.50 August 2024

KOBE Biomedical Innovation Cluster newsletter vol.50
- August 2024 -

vol.50 August 2024

Hello!

Very hot summer in Japan is going to end finally and exhibition season will start !

We will exhibit at Medical Fair Asia, one of the largest medical and health care exhibition in the South East Asia to be held on Sep 11-13 in Singapore. We will bring 5 co-exhibitors including 2 startups. We have been preparing for this exhibition and we hope good matching and collaboration will happen !

If you missed our past issues of KBIC newsletter, please visit Newsletter Archive.

FBRI Editorial Team

NEWS

United Immunity enters into the Research Collaboration Agreement with AstraZeneca

United Immunity (Tokyo, Japan) enters into the Research Collaboration Agreement with AstraZeneca. See further information on the Japanese press release.
(https://www.astrazeneca.co.jp/media/press-releases1/2024/2024072601.html)
United Immunity develops its proprietary active targeting pullulan lipid nanoparticle (LNP) selective to myeloid cells as its Myeloid Targeting Platform™.

Sysmex Group’s Largest Manufacturing Base Completed in India

Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano) announces today the completion of construction of a new manufacturing base in India, which is the Group’s first factory capable of producing both reagents and instruments.

The new manufacturing base has the largest total floor area of all the Sysmex Group’s manufacturing bases outside Japan. It has the capacity to significantly expand the range of reagents produced and to produce instrument products in response to the Make in India policy of the Government of India. This will strengthen our supply capacity for robust testing demand and aim for accelerated business expansion and sustained growth in India.

Tokyo Medical and Dental University and Celaid Therapeutics Inc. Joint Research Agreement on Research and Development of Gene-modified Cell Therapy Using Human Bone Marrow Hematopoietic Stem Cells (HSCs)

Tokyo Medical and Dental University (TMDU) and Celaid Therapeutics Inc. (Celaid) are pleased to announce the signing of a joint research agreement.

PRESS RELEASE（PDF）

This agreement was established for research and development of novel gene-modified cell therapies using human bone marrow HSCs for inborn errors of immunity* and is expected to spur next-generation gene-modified cell therapy development in Japan. Distinguished Research Professor Tomohiro Morio with his team at the TMDU Laboratory of Immunology and Molecular Medicine and Celaid will jointly explore new treatments for inherited immune disorders through the application of Celaid’s novel HSC expansion technology to HSCs isolated from human bone marrow. These cells will be evaluated after gene modification.